Who is sponsoring NCT02831283?

NCT02831283 is sponsored by Patrick Lao.

What condition does NCT02831283 study?

NCT02831283 studies Alzheimer's Disease.

What drugs are being tested in NCT02831283?

Interventions: 11C-PBR28, 18F-Florbetaben, Lumbar puncture (optional).

What is the status of NCT02831283?

NCT02831283 is currently COMPLETED.

Last reviewed 2025-02-12 · How we verify

Imaging Inflammation in Elders With Different Clinical and Biomarker Profiles of Alzheimer's Disease

NCT02831283 Phase 2 COMPLETED Results posted

This study is being done to learn about inflammation and amyloid in Alzheimer's disease. A type of brain scan called a PET scan is used measure 1) inflammation and 2) abnormal accumulation of a the amount of a certain protein fragment called beta-amyloid (plaques) in the brain. These are thought to be involved in Alzheimer's disease. The investigators will also perform brain MRI and do tests to measure the participants' memory and thinking.

Details

Lead sponsor	Patrick Lao
Phase	Phase 2
Status	COMPLETED
Enrolment	60
Start date	2016-06
Completion	2022-12

Conditions

Alzheimer's Disease

Interventions

11C-PBR28
18F-Florbetaben
Lumbar puncture (optional)

Primary outcomes

11C-PBR28 Binding — Up to 1 year from screening
In vivo quantification radioligand binding to TSPO expression on microglia in the brain, reported as standardized uptake value ratio (SUVR).

Countries

United States